Dr. Reddy's Labs Receives FDA Form 483

  Published 1 year ago

Dr. Reddy's Laboratories' Miryalaguda API facility in India underwent a US FDA GMP inspection (May 19-24, 2025), resulting in a Form 483 with two observations. The company plans to address them promptly.

  • FDA inspected Dr. Reddy’s Miryalaguda facility.
  • Form 483 issued with 2 observations.
  • The company will address observations quickly.
You might like these

Sensex, Nifty End Flat; L&T Lifts Mood

Alembic Gets USFDA Nod for Drug

Lupin's Generic Lotemax SM Exclusivity & Launch

India's Forex Reserves Dip $9.3 Billion

Ola Roadster X: Deliveries Begin & Key Features

Suzuki Swift Production Halt: Rare Earths Blamed

Airtel's Xtelify Launches Cloud, AI Platforms

News that matters the most ⚡